Osprey’s DyeVert contrast minimization devices align with GE’s iodinated X-ray contrast media to offer a technology platform to address acute kidney injury (AKI) following interventional coronary angiograms in patients with chronic kidney disease (CKD), according to a news release.
Under a four-year agreement, GE Healthcare will commercialize Osprey’s DyeVert portfolio of FDA-cleared devices for reducing contrast exposure and monitoring cumulative dye dose specific to each patient’s kidney function.
The exclusive distribution agreement allows GE Healthcare to commercialize Osprey’s products within Europe, Russia, Middle East, Africa, Central Asia and Turkey. As Osprey develops new products, GE Healthcare will have the right of first refusal to distribute and promote those products within the regions.
Osprey president and CEO Mike McCormick said in the release that the company is “pleased to be partnering with GE Healthcare” in the commercialization efforts.
“GE Healthcare and Osprey share a similar goal rooted in improving patient outcomes” added president & CEO of GE Healthcare’s pharmaceutical diagnostics business Kevin O’Neill. “Both our product portfolios and educational efforts, which are aligned with cardiology guidelines for AKI minimization, offer interventional cardiologists the opportunity to safely image patients by reducing the risk of AKI.”